<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02858154</url>
  </required_header>
  <id_info>
    <org_study_id>CIN001-HFNC and OSA</org_study_id>
    <nct_id>NCT02858154</nct_id>
  </id_info>
  <brief_title>Comparison of High Flow Nasal Cannula Therapy to Nasal Oxygen as a Treatment for Obstructive Sleep Apnea in Infants</brief_title>
  <official_title>Comparison of High Flow Nasal Cannula Therapy to Nasal Oxygen (O2) as a Treatment for Obstructive Sleep Apnea (OSA) in Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Mercy Hospital Kansas City</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a small pilot study that will compare High Flow Nasal Cannula (HFNC) therapy to&#xD;
      oxygen nasal cannula therapy on infants who have obstructive sleep apnea (OSA) and are&#xD;
      scheduled for a clinically ordered sleep study called polysomnography (PSG). The HFNC&#xD;
      procedure uses humidified room air delivered by nasal cannula at higher pressures and will&#xD;
      test if HFNC can control OSA in infants better or as well as low flow nasal oxygen, the&#xD;
      current clinical standard of care. All the infants in the study will have a brief test period&#xD;
      of about 3 to 4 hours with the HFNC before participants begin their standard clinical PSG for&#xD;
      titration of oxygen by nasal cannula for treatment of OSA.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current standard of care for treating OSA in infants less than 6 months and frequently up&#xD;
      to 12 months of age is with a continuous flow of oxygen by nasal cannula. This is generally&#xD;
      referred to as nasal continuous positive airway pressure or NCPAP. A nasal cannula is used&#xD;
      with oxygen at low flows of between 1/4 to 1 liter per minute (l/m) to deliver supplemental&#xD;
      oxygen to reduce oxygen desaturations associated with apneic episodes and to provide a&#xD;
      positive pressure flow to maintain an open airway.&#xD;
&#xD;
      High Flow Nasal Cannula (HFNC) therapy is a non-invasive treatment providing respiratory&#xD;
      support. In this study, HFNC is designed to administer a heated and humidified mixture of air&#xD;
      at a flow higher than the patient's inspiratory flow. There is currently no single, simple&#xD;
      definition of high flow. In infants, it usually refers to a flow of &gt;2 l/min and in children&#xD;
      it is considered &gt;6 l/min. High flow presents several advantages over conventional 'low-flow'&#xD;
      oxygen therapy in terms of humidification, oxygenation, gas exchange, and breathing pattern.&#xD;
      Several studies have shown that a flow higher than the patient's inspiratory flow provides&#xD;
      better oxygen delivery than low-flow oxygen therapy or high-concentration oxygenation mask.&#xD;
      This observation has been explained as the effect of a high flow on the oropharyngeal dead&#xD;
      space, washing out oxygen depleted gas and reducing carbon dioxide (CO2) rebreathing. The&#xD;
      extrathoracic dead space is proportionally two to three times greater in children than in&#xD;
      adults. It may measure up to 3 mL/kg in newborns and becomes similar to the adult volume only&#xD;
      after 6 years of age (0.8 mL/kg). Consequently, the younger a child is, the greater the&#xD;
      effect of a high flow on oxygenation and CO2 clearance.&#xD;
&#xD;
      This pilot study is to compare standard of care low flow nasal oxygen to the effectiveness of&#xD;
      HFNC therapy in infants aged 12 months and younger to treat OSA. The study intervention will&#xD;
      occur for approximately 3 to 4 hours immediately prior to a scheduled clinical PSG. Subjects&#xD;
      will be prepared for standard clinical PSG and after asleep, the intervention will be&#xD;
      titration of room air at different pressure flows delivered by a HFNC system. At the end of&#xD;
      the research portion of the PSG, the clinical PSG will begin with the standard of care&#xD;
      treatment, the nasal oxygen titration for OSA. The results of the clinical PSG will serve as&#xD;
      control comparison for the research intervention.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">December 26, 2021</completion_date>
  <primary_completion_date type="Actual">September 26, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average AHI Diagnostic Sleep Study Compared to Average AHI With Improvement in OSA With HFNC</measure>
    <time_frame>End of visit (12 hours)</time_frame>
    <description>AHI will be compared from diagnostic sleep study to average AHI with improvement in OSA with HFNC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AHI From Diagnostic Sleep Study Compared to AHI From Sleep Study Improvement in OSA With Low Flow Oxygen Via Nasal Cannula</measure>
    <time_frame>end of visit (12 hours)</time_frame>
    <description>All subjects will receive 3-4 hours of experimental treatment (HFNC) during a research portion of a PSG and then for the 6-8 hours of clinically ordered PSG will receive low flow oxygen by nasal cannula.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>HFNC and low flow oxygen by nasal cannula</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All subjects will receive 3-4 hours of experimental treatment (HFNC) during a research portion of a PSG and then for the 6-8 hours of clinically ordered PSG will receive active comparator (low flow oxygen by nasal cannula)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HFNC</intervention_name>
    <description>All subjects will have a 3-4 hour intervention of HFNC to test effectiveness and safety for treating OSA</description>
    <arm_group_label>HFNC and low flow oxygen by nasal cannula</arm_group_label>
    <other_name>High Flow Nasal Cannula</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Low flow oxygen by nasal cannula</intervention_name>
    <description>All subjects will have a 6 to 8 hours intervention during the clinically scheduled PSG of titration of oxygen by nasal cannula (standard of care) to manage sleep apnea</description>
    <arm_group_label>HFNC and low flow oxygen by nasal cannula</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Infants ≤ 12 months&#xD;
&#xD;
          -  Diagnosis of OSA from previous PSG&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Infants who on previous PSG had central apneas &gt; 50% of the AHI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>12 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neepa Gurbani, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zarmina Ehsan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Mercy Hospital Kansas City</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Sreenan C, Lemke RP, Hudson-Mason A, Osiovich H. High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure. Pediatrics. 2001 May;107(5):1081-3.</citation>
    <PMID>11331690</PMID>
  </reference>
  <reference>
    <citation>Kotecha SJ, Adappa R, Gupta N, Watkins WJ, Kotecha S, Chakraborty M. Safety and Efficacy of High-Flow Nasal Cannula Therapy in Preterm Infants: A Meta-analysis. Pediatrics. 2015 Sep;136(3):542-53. doi: 10.1542/peds.2015-0738. Epub 2015 Aug 17. Review.</citation>
    <PMID>26283781</PMID>
  </reference>
  <reference>
    <citation>Milési C, Boubal M, Jacquot A, Baleine J, Durand S, Odena MP, Cambonie G. High-flow nasal cannula: recommendations for daily practice in pediatrics. Ann Intensive Care. 2014 Sep 30;4:29. doi: 10.1186/s13613-014-0029-5. eCollection 2014. Review.</citation>
    <PMID>25593745</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 25, 2016</study_first_submitted>
  <study_first_submitted_qc>August 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2016</study_first_posted>
  <results_first_submitted>June 4, 2021</results_first_submitted>
  <results_first_submitted_qc>July 28, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 23, 2021</results_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital Medical Center, Cincinnati</investigator_affiliation>
    <investigator_full_name>Neepa Gurbani, DO</investigator_full_name>
    <investigator_title>DO</investigator_title>
  </responsible_party>
  <keyword>OSA</keyword>
  <keyword>obstructive sleep apnea</keyword>
  <keyword>infants</keyword>
  <keyword>high flow nasal cannula</keyword>
  <keyword>HFNC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 12, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/54/NCT02858154/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>HFNC Followed by Clinically Ordered Low Flow Oxygen Via Nasal Cannula</title>
          <description>All subjects received HFNC followed by clinically ordered low flow oxygen via nasal cannula.&#xD;
HFNC: All subjects will have a 3-4 hour intervention of HFNC to test effectiveness and safety for treating OSA&#xD;
Low flow oxygen by nasal cannula: All subjects will have a 6 to 8 hours intervention during the clinically scheduled PSG of titration of oxygen by nasal cannula (standard of care in infants) to control sleep apnea and desaturations</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>HFNC 3-4 Hours</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Clinically Ordered PSG/Low Flow Oxygen</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Children With OSA Receiving HFNC and Low Flow Oxygen With Nasal Cannula</title>
          <description>All subjects will receive 3-4 hours of experimental treatment (HFNC) during a research portion of a PSG and then for the 6-8 hours of clinically ordered PSG will receive active comparator (oxygen by nasal cannula)&#xD;
HFNC: All subjects will have a 3-4 hour intervention of HFNC to test effectiveness and safety for treating OSA&#xD;
Oxygen by Cannula: All subjects will have a 6 to 8 hours intervention during the clinically scheduled PSG of titration of oxygen by nasal cannula (standard of care) to control sleep apnea and desaturations</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.33" spread="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Average AHI Diagnostic Sleep Study Compared to Average AHI With Improvement in OSA With HFNC</title>
        <description>AHI will be compared from diagnostic sleep study to average AHI with improvement in OSA with HFNC</description>
        <time_frame>End of visit (12 hours)</time_frame>
        <population>We analyzed subjects who had improvement in AHI with HFNC compared to the diagnostic study.</population>
        <group_list>
          <group group_id="O1">
            <title>Average AHI Diagnostic Sleep Study Compared to Average AHI With Improvement in OSA With HFNC</title>
            <description>All subjects will receive 3-4 hours of experimental treatment (HFNC) during a research portion of a PSG and then for the 6-8 hours of clinically ordered PSG will receive low flow oxygen by nasal cannula.</description>
          </group>
        </group_list>
        <measure>
          <title>Average AHI Diagnostic Sleep Study Compared to Average AHI With Improvement in OSA With HFNC</title>
          <description>AHI will be compared from diagnostic sleep study to average AHI with improvement in OSA with HFNC</description>
          <population>We analyzed subjects who had improvement in AHI with HFNC compared to the diagnostic study.</population>
          <units>events/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AHI on diagnostic study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" spread="5.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AHI with improvement in OSA with HFNC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.12" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AHI From Diagnostic Sleep Study Compared to AHI From Sleep Study Improvement in OSA With Low Flow Oxygen Via Nasal Cannula</title>
        <description>All subjects will receive 3-4 hours of experimental treatment (HFNC) during a research portion of a PSG and then for the 6-8 hours of clinically ordered PSG will receive low flow oxygen by nasal cannula.</description>
        <time_frame>end of visit (12 hours)</time_frame>
        <population>Compared AHI with low flow oxygen via nasal cannula compared to diagnostic sleep study AHI.</population>
        <group_list>
          <group group_id="O1">
            <title>Average AHI Diagnostic Study Compared to Average AHI With Improvement in OSA With Low Flow Oxygen</title>
            <description>All subjects will receive 3-4 hours of experimental treatment (HFNC) during a research portion of a PSG and then for the 6-8 hours of clinically ordered PSG will receive low flow oxygen by nasal cannula.</description>
          </group>
        </group_list>
        <measure>
          <title>AHI From Diagnostic Sleep Study Compared to AHI From Sleep Study Improvement in OSA With Low Flow Oxygen Via Nasal Cannula</title>
          <description>All subjects will receive 3-4 hours of experimental treatment (HFNC) during a research portion of a PSG and then for the 6-8 hours of clinically ordered PSG will receive low flow oxygen by nasal cannula.</description>
          <population>Compared AHI with low flow oxygen via nasal cannula compared to diagnostic sleep study AHI.</population>
          <units>events/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AHI from diagnostic sleep study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.44" spread="5.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AHI from improvement in OSA with low flow oxygen by nasal cannula</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="3.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 hours (duration of intervention)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>HFNC for the First 3-4 Hours of the Study Followed by Clinically Ordered Low Flow Oxygen.</title>
          <description>All subjects will receive 3-4 hours of experimental treatment (HFNC) during a research portion of a PSG and then 6-8 hours of clinically ordered PSG with low flow oxygen by nasal cannula for the remainder of the study. Since both interventions were done on the same night the sleep study with the first 3-4 hours of the sleep study with HFNC and the remainder 6-8 hours with clinically ordered PSG with low flow oxygen via nasal cannula the adverse events are reported for the duration of the study interventions.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Neepa Gurbani</name_or_title>
      <organization>Cincinnati Children's Hospital Medical Center</organization>
      <phone>513-736-1814</phone>
      <email>Neepa.Gurbani@cchmc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

